Mitsubishi Tanabe to take majority stake in Phillip Morris-backed Medicago
This article was originally published in Scrip
Mitsubishi Tanabe Pharma (MTPC), in an agreement with US tobacco company Phillip Morris Investments, is set to acquire a majority stake in clinical stage biopharmaceutical firm Medicago, which develops vaccines using tobacco and alfalfa plants. The transaction values the firm at CAN357m (US$344m). The move will take Medicago private.
You may also be interested in...
Coronavirus Update: WHO Suspends Hydroxychloroquine Trial, Novavax Launches Phase I/II Vaccine Study
Mounting evidence that President Trump's 'game changer' does more harm than good for COVID-19 patients. Novovax and Medicago among the latest vaccine developers to report progress.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.